Appoints Jonathan Burgin as Chief Financial Officer
Tel-Aviv, Israel – March 15, 2021 – Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced the appointment of Jonathan Burgin, MBA, as the new Chief Financial Officer of the company.
“Jonathan’s appointment comes at an intriguing time for
Tarsier Pharma, as we grow the organization and advance our lead drug candidate
TRS01 for uveitic glaucoma towards phase-III clinical trials, while continuing
to develop transformative treatments based on our novel molecular platform to
address inflammatory ocular diseases. Thanks to Jonathan’s expertise and
leadership experience especially in financial roles, he will be instrumental in
expediting our growth and commercial success,” stated Daphne Haim-Langford,
PhD, CEO and Chairperson at Tarsier.
Jonathan Burgin is a seasoned C level Executive bringing with
him over 20 years of managerial experience and leadership, including 16 years
in life science companies. Most recently he served in the position of CFO and
COO at Anchiano Therapeutics, a clinical stage biopharmaceutical company
developing drugs against cancer (Nasdaq: ANCN), and is a board member of
Cellect Biotechnology (Nasdaq: APOP), a cell therapy company. Jonathan has
raised over $200 million in capital in support of advancing companies’ missions.
“This is a very exciting time to be joining Tarsier Pharma
management team,” said Jonathan. “Having a solid business foundation, a growing
pipeline, and as several key milestones are expected in the next year, I am
looking forward to working together to achieve the Company’s next level of
growth”.
About Tarsier Pharma
Tarsier Pharma was established in 2016 and is focused on
developing TRS, a breakthrough, bio-inspired platform technology for the
treatment of blinding ocular diseases.
The company’s investors include a wholly-owned subsidiary
company of Sun Pharmaceutical Industries Limited, BioLight Life Sciences Ltd,
as well as private investors and family offices. The company has received
funding from the European Union’s Horizon 2020 research and innovation program
under grant agreement No. 879598.
